1
Coerver, E M E, Wessels, M H J, van Lierop, Z Y G, van Kempen, Z L E, Killestein, J, Strijbis, E M M
Veröffentlicht in: Coerver , E M E , Wessels , M H J , van Lierop , Z Y G , van Kempen , Z L E , Killestein , J & Strijbis , E M M 2021 , ' Natalizumab discontinuation in a Dutch real-world cohort ' , Multiple Sclerosis and Related Disorders , vol. 52 , 102974 , pp. 102974 . https://doi.org/10.1016/j.msard.2021.102974 , https://doi.org/10.1016/j.msard.2021.102974;
2021
Veröffentlicht in: Coerver , E M E , Wessels , M H J , van Lierop , Z Y G , van Kempen , Z L E , Killestein , J & Strijbis , E M M 2021 , ' Natalizumab discontinuation in a Dutch real-world cohort ' , Multiple Sclerosis and Related Disorders , vol. 52 , 102974 , pp. 102974 . https://doi.org/10.1016/j.msard.2021.102974 , https://doi.org/10.1016/j.msard.2021.102974;
2021